VERTEX PHARMACEUTICALS INC / MA Logo

VERTEX PHARMACEUTICALS INC / MA

Develops transformative medicines for serious diseases, specializing in cystic fibrosis.

VRTX | US

Overview

Corporate Details

ISIN(s):
US92532F1003
LEI:
Country:
United States of America
Address:
50 NORTHERN AVENUE, 2210 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercializes transformative medicines for people with serious diseases. The company is a recognized leader in the treatment of cystic fibrosis (CF), having developed a portfolio of therapies that treat the underlying cause of the disease. Vertex focuses on scientific innovation and invests in research for specialty market diseases with high unmet medical needs, leveraging a deep understanding of causal human biology. Its research and development pipeline extends beyond CF to include other serious conditions such as sickle cell disease, beta-thalassemia, acute pain, and type 1 diabetes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all VERTEX PHARMACEUTICALS INC / MA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for VERTEX PHARMACEUTICALS INC / MA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for VERTEX PHARMACEUTICALS INC / MA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.